5-アミノレブリン酸塩酸塩
Aminolevulinic Acid Hydrochloride
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
5451-09-2- 標準SMILES
Cl.NCC(=O)CCC(=O)O- InChIKey
ZLHFONARZHCSET-UHFFFAOYSA-N- 分子式
- C5H10ClNO3
- 平均分子量
- 167.59 g/mol
- 単同位体質量
- 167.03492086
概要
5-aminolevulinic acid hydrochloride is a hydrochloride that is the monohydrochloride of 5-aminolevulinic acid. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. It has a role as an antineoplastic agent, a photosensitizing agent, a dermatologic drug and a prodrug. It contains a 5-ammoniolevulinic acid.
名称と識別子
- 優先名称
- Aminolevulinic Acid Hydrochloride
- IUPAC
- 5-amino-4-oxopentanoic acid;hydrochloride
- 現地名
- 5-アミノレブリン酸塩酸塩
- 英語名
- 5-Aminolevulinic acid hydrochloride
- 分子式
- C5H10ClNO3
- 分子量
- 167.59
名称と別名
5-Aminolevulinic acid hydrochloride5451-09-2Aminolevulinic acid hydrochloride5-Amino-4-oxopentanoic acid hydrochlorideLevulanLevulan Kerastickdelta-Aminolevulinic acid hydrochlorideAminolevulinic Acid HClAmeluzAlaglioGleolanAlabel
名称をさらに表示
5-アミノレブリン酸塩酸塩4-カルボキシ-2-オキソブチルアミン·塩酸塩4-カルボキシ-2-オキソブチルアンモニウム=クロリド5-アミノ-4-オキソペンタン酸=塩酸塩5-アミノ-4-オキソペンタン酸·塩酸塩5‐アミノレブリン酸塩酸塩アミノレブリン酸HCL5-アミノ-4-オキソペンタン酸塩酸塩5-アミノレブリン酸塩酸塩 SALTΔ-アミノレブリン酸塩酸塩5-アミノレブリン酸 塩酸塩5-アミノレブリン酸塩酸塩, 99%アミノレブリン酸塩酸塩アミノレブリン酸塩酸塩 (JAN)5-アミノレブリン酸・塩酸塩4-カルボキシ-2-オキソブチルアミン・塩酸塩5-アミノ-4-オキソペンタン酸・塩酸塩5-Ala5-AMINOLEVULINIC ACID HCL5-AminolevulinicGliolaninic acid hydrochLevuL
物性
構造計算による物性補完中
- 極性表面積
- 80.4 Ų
- 水素結合供与体数
- 3
- 水素結合受容体数
- 4
- 回転可能結合数
- 4
- 重原子数
- 10
- 形式電荷
- 0
- 複雑度
- 121
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Dermatologic Agents; Photosensitizing Agents
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
物理化学的性質
- 融点
- 150 °C · ~150 °C (dec.)
- 闪点
- 155 · 155-157°C
- 貯蔵温度
- -20 °C · -20°C
- 溶解性
- 2 O: · H2O: 50 mg/mL
- 外見
- 粉
- 色
- 白色～淡黄色
- PH
- pH (10g/l, 25℃) : 2.5～3.0
- 水溶解度
- ジメチルスルホキシド、メタノール、水に可溶。
- Decomposition
- 155 · 155-157 ºC
- Merck
- 14 · 14,446
- BRN
- 3690651 · 3690651
- 安定性
- Hygroscopic
- 化粧品成分の機能
- 肌を保護する抗菌剤ヘアコンディショニング皮脂抑制
- InChI
- 1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H
- InChIKey
- ZLHFONARZHCSET-UHFFFAOYSA-N
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
危険有害性情報
Regulatory InformationPentanoic acid, 5-amino-4-oxo-, hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Pentanoic acid, 5-amino-4-oxo-, hydrochloride: Environment tier I assessment
毒性情報
Exposure RoutesOral bioavailability is 50-60%.
Toxicity Summary
According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT).
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
安全データ
- F
- 3-8-10
- wgk
- 3
- rtecs
- OI1640000
化学と産業
薬理情報
Metabolism/MetabolitesFollowing topical administration, synthesis into protoporphyrin IX takes place in situ in the skin.
Half Life: Mean half-life is 0.70 ± 0.18 h after the oral dose and 0.83 ± 0.05 h after the intravenous dose.
FDA Pharmacological Classification
AMINOLEVULINIC ACID HYDROCHLORIDE
Optical Imaging Agent [EPC]; Porphyrin Precursor [EPC]; Porphyrinogens [CS]; Fluorescence Contrast Activity [MoA]
MeSH Pharmacological Classification
Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms.
用途と製造
UsesAminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
応用分野
使用5-Aminolevulinic acid hydrochloride finds an important role as a precursor in the synthesis of tetrapyrroles such as chlorophyll and heme. It is widely utilized in photodynamic therapy of diseases namely, Pagets disease and human papillomavirus (HPV) infection-associated cervical condylomata acuminata.
調製方法
純化方法Dry ALA-HCl in a vacuum desiccator over P2O5 overnight, then crystallise it by dissolving it in cold EtOH and adding dry Et2O. Also crystallis
上流・下流製品情報
関連反応
112 件
化合物ノート
読み込み中…